SG11201505856TA - Novel binding proteins for pcsk9 - Google Patents

Novel binding proteins for pcsk9

Info

Publication number
SG11201505856TA
SG11201505856TA SG11201505856TA SG11201505856TA SG11201505856TA SG 11201505856T A SG11201505856T A SG 11201505856TA SG 11201505856T A SG11201505856T A SG 11201505856TA SG 11201505856T A SG11201505856T A SG 11201505856TA SG 11201505856T A SG11201505856T A SG 11201505856TA
Authority
SG
Singapore
Prior art keywords
pcsk9
binding proteins
novel binding
novel
proteins
Prior art date
Application number
SG11201505856TA
Inventor
Gabriele Matschiner
Christine Rothe
Andreas Hohlbaum
Aiba Rachida Siham Bel
Marlon Hinner
Andrea Allersdorfer
Bradley Lunde
Alexander Wiedenmann
Shinji Yamaguchi
Takahide Aburatani
Ryuji Hashimoto
Tohru Takahashi
Chikako Nagasaki
Futoshi Nara
Tomohiro Nishizawa
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of SG11201505856TA publication Critical patent/SG11201505856TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
SG11201505856TA 2013-03-14 2014-03-13 Novel binding proteins for pcsk9 SG11201505856TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361781511P 2013-03-14 2013-03-14
EP13175023 2013-07-04
PCT/EP2014/055013 WO2014140210A1 (en) 2013-03-14 2014-03-13 Novel binding proteins for pcsk9

Publications (1)

Publication Number Publication Date
SG11201505856TA true SG11201505856TA (en) 2015-08-28

Family

ID=48703321

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201505856TA SG11201505856TA (en) 2013-03-14 2014-03-13 Novel binding proteins for pcsk9

Country Status (15)

Country Link
US (3) US9150629B2 (en)
EP (1) EP2968490A1 (en)
JP (1) JP6619650B2 (en)
KR (1) KR20150131151A (en)
CN (1) CN105246503A (en)
AU (1) AU2014230460B2 (en)
BR (1) BR112015021681A2 (en)
CA (1) CA2905186A1 (en)
HK (1) HK1213194A1 (en)
IL (1) IL241329A0 (en)
MX (1) MX2015012420A (en)
PH (1) PH12015501687A1 (en)
RU (1) RU2015142437A (en)
SG (1) SG11201505856TA (en)
WO (1) WO2014140210A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
CN105246503A (en) 2013-03-14 2016-01-13 第一三共株式会社 Novel binding proteins for pcsk9
EP3102224B1 (en) * 2013-12-20 2019-02-20 NephroGenesis, LLC. Apparatuses for kidney dialysis and lipocalin protein for use in the prevention or treatment of uremia by dialysis
US9398085B2 (en) 2014-11-07 2016-07-19 Ringcentral, Inc. Systems and methods for initiating a peer-to-peer communication session
JP6884708B2 (en) 2015-05-04 2021-06-09 ピエリス ファーマシューティカルズ ゲーエムベーハー CD137-specific protein
EP3793612A4 (en) * 2018-05-16 2022-03-02 LIB Therapeutics, LLC Compositions comprising pcsk9-binding molecules and methods of use
WO2019246386A1 (en) 2018-06-21 2019-12-26 Ra Pharmaceuticals Inc. Cyclic polypeptides for pcsk9 inhibition
JOP20190150A1 (en) * 2018-06-21 2019-12-21 Merck Sharp & Dohme Pcsk9 antagonist compounds
WO2019246387A1 (en) 2018-06-21 2019-12-26 Ra Pharmaceuticals, Inc. Cyclic peptides for pcsk9 inhibition
CR20210441A (en) 2019-01-18 2022-03-11 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
AU2020253034A1 (en) 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (en) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk Production of normal human serum albumin a through gene recombination
FR2649991B2 (en) 1988-08-05 1994-03-04 Rhone Poulenc Sante USE OF STABLE DERIVATIVES OF PLASMID PKD1 FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS IN YEASTS OF THE GENUS KLUYVEROMYCES
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
DE4417598A1 (en) 1994-05-19 1995-12-14 Max Planck Gesellschaft Use of the tetracycline promoter for the stringently regulated production of recombinant proteins in prokaryotic cells
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
SI1087778T1 (en) 1998-06-08 2006-02-28 Hoffmann La Roche Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (en) 1999-06-08 2001-01-11 Arne Skerra Muteins of the bilin binding protein
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AT411852B (en) 2002-02-12 2004-06-25 Didosyan Yuri S Dr METHOD AND DEVICE FOR CHANGING THE POLARIZATION STATE OF LIGHT WITH A MAGNETICALLY ONE-AXIS CRYSTAL
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
EP1658308A1 (en) 2003-08-25 2006-05-24 Pieris ProteoLab AG Muteins of a bilin-binding protein with affinity for a given target
EP1814988A2 (en) 2004-11-26 2007-08-08 Pieris AG Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
CA2622441A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
EP1996613B1 (en) * 2006-03-20 2014-04-30 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
AU2007280398B2 (en) 2006-08-01 2012-05-10 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
US20100136028A1 (en) * 2006-11-07 2010-06-03 Sparrow Carl P Antagonists of pcsk9
EP2083859A4 (en) * 2006-11-07 2010-11-24 Merck Sharp & Dohme Antagonists of pcsk9
MX2009010957A (en) * 2007-04-13 2009-10-29 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9).
US8937153B2 (en) 2007-07-31 2015-01-20 Affibody Ab Compositions, methods and uses
WO2011154420A2 (en) * 2010-06-08 2011-12-15 Pieris Ag Tear lipocalin muteins binding il-4 r alpha
US9211344B2 (en) 2010-07-09 2015-12-15 Affibody Ab Polypeptides
SG11201403887WA (en) * 2012-01-09 2014-08-28 Pieris Ag Methods for preventing, treating or diagnosing disorders
CN105246503A (en) 2013-03-14 2016-01-13 第一三共株式会社 Novel binding proteins for pcsk9

Also Published As

Publication number Publication date
JP2016519051A (en) 2016-06-30
US20140288008A1 (en) 2014-09-25
US9598476B2 (en) 2017-03-21
MX2015012420A (en) 2016-06-02
RU2015142437A (en) 2017-04-27
CN105246503A (en) 2016-01-13
AU2014230460B2 (en) 2018-04-05
BR112015021681A2 (en) 2017-11-14
JP6619650B2 (en) 2019-12-11
US9150629B2 (en) 2015-10-06
WO2014140210A1 (en) 2014-09-18
US20170173112A1 (en) 2017-06-22
AU2014230460A1 (en) 2015-09-10
IL241329A0 (en) 2015-11-30
US20160024161A1 (en) 2016-01-28
KR20150131151A (en) 2015-11-24
PH12015501687A1 (en) 2015-10-19
EP2968490A1 (en) 2016-01-20
HK1213194A1 (en) 2016-06-30
CA2905186A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
IL281703A (en) Novel heterodimeric proteins
IL284301A (en) Heterodimeric proteins
IL240838A0 (en) Anti-lag-3 binding proteins
HK1225641A1 (en) Gitr antigen binding proteins
IL240915A0 (en) Dual specific binding proteins directed against tnfɑ
HK1213194A1 (en) Novel binding proteins for pcsk9 pcsk9
SG11201505198WA (en) Protein purification methods
GB201302597D0 (en) Novel Synthetic Proteins
EP3068886A4 (en) Aptamers for binding flavivirus proteins
HK1218920A1 (en) Improved tnf binding proteins tnf
GB201308057D0 (en) Protein
GB201401955D0 (en) Protein
GB201315532D0 (en) Methods for detecting proteins
GB201418608D0 (en) Peridinin-chlorophyll binding proteins
GB201314945D0 (en) Protein crystals
PT2991505T (en) Protein enrichment
GB201302031D0 (en) Protein
GB201302030D0 (en) Protein
GB201303977D0 (en) Binding polypeptides
GB201314294D0 (en) Binding surfaces
GB201215901D0 (en) Protein modification